Who we are
What we do
About Cure Leukaemia
Founded in 2003 by Professor Charlie Craddock CBE and patients Graham Silk and Michael Woolley, Cure Leukaemia helps to bring pioneering drug and transplant treatments to blood cancer patients across the United Kingdom. The charity funds the Trials Acceleration Programme (TAP) network comprising 12 blood cancer centres across the UK.
As a result, specialist research nurses are funded at these centres allowing clinical trials of pioneering and potentially life-saving treatments for blood cancer to run giving patients from a catchment area of over 20 million access to these new drugs. Cure Leukaemia also funds the TAP network’s Hub based at the internationally renowned Centre for Clinical Haematology at Queen Elizabeth Hospital in Birmingham to co-ordinate these pioneering trials.
Without the expert research nurses to ensure patients are constantly monitored and cared for; these trials would not run, and patients would miss the opportunity to access potentially life-saving therapies. The aim of Cure Leukaemia is to raise money to fund more research nurses and provide world-class treatment for its patients. Only by funding more nurses in more hospitals, can more blood cancer patients benefit from access to potentially life-saving treatment.
In 2017 Cure Leukaemia raised an additional £1m to help fully fund the expansion of the Centre for Clinical Haematology. The transformational £3.4m project doubled the Centre’s capacity for blood cancer patients treated, clinical trials opened, and research nurses employed. Capacity for an additional 75 jobs has been created, and it has allowed stem cell transplants to be performed as an outpatient for the first time.
Also in 2017, Cure Leukaemia was selected to be one of Deutsche Bank’s Charities of the Year for 2018 and 2019, a partnership that has raised £2m and made its nationwide transition possible.